Charles River Laboratories International, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NYSE
Birgit Girshick, Chief Executive Officer and a Director of Charles River Laboratories International, Inc., sold 6,500 shares of common stock on August 11, 2026 for $279.90 per share.
NYSE
Shannon M Parisotto, CEVP, Disc & Safety Assessment of Charles River Laboratories International, Inc., sold 3,714 shares of common stock on August 11, 2026 for $279.66 per share.
NYSE
Joseph W Laplume, EVP, Corp Strategy & Develop of Charles River Laboratories International, Inc., reported a transaction in 257 shares of common stock on August 10, 2026.
NYSE
James C Foster, a Director of Charles River Laboratories International, Inc., sold 28,733 shares of common stock on August 10, 2026 for $275.00 per share.
NYSE
Michael Gunnar Knell, SVP, Finance and CAO of Charles River Laboratories International, Inc., sold 6,645 shares of common stock on August 6, 2026.
NYSE
Shannon M Parisotto, CEVP, Disc & Safety Assessment of Charles River Laboratories International, Inc., sold 5,046 shares of common stock on August 5, 2026 for $263.00 per share.
NYSE
Director James C. Foster of Charles River Laboratories International, Inc. reported a sale of 75,000 common shares, executed under a pre-established Rule 10b5-1 trading plan.
NYSE
Charles River Laboratories director James C. Foster reported a series of transfers of common stock to various trusts on June 5, 2026, involving over 183,000 shares.
NYSE
Birgit Girshick, CEO of Charles River Laboratories, transferred 3,386 shares to a revocable trust she controls.
NYSE
Shannon M. Parisotto, EVP of Discovery & Safety Assessment at Charles River Laboratories, reported a transfer of 1,529 common shares to a revocable trust.
NYSE
Director Steven Barg acquired 422 shares of Charles River Laboratories International, Inc. as part of a stock-based compensation plan for director service fees.
NYSE
Glenn Coleman, EVP & Chief Financial Officer of Charles River Laboratories International, Inc., acquired 6,640 shares of common stock.
NYSE
Mark Mintz, EVP and Chief Information Officer at Charles River Laboratories, reported transactions involving company common stock.
NYSE
Joseph W. LaPlume, EVP of Corp Strategy & Develop at Charles River Laboratories, reported transactions involving common stock.
NYSE
Michael Knell, SVP, Finance and CAO of Charles River Laboratories International, Inc., reported transactions involving common stock, including acquisitions and dispositions.
NYSE
Birgit Girshick, CEO of Charles River Laboratories, reported transactions involving the acquisition and disposition of company common stock.
NYSE
Director James C. Foster reported transactions involving Charles River Laboratories International, Inc. common stock.
NYSE
Victoria L. Creamer, EVP & Chief People Officer at Charles River Laboratories, reported transactions involving common stock, including the acquisition of 5,135 shares.
NYSE
Shannon M. Parisotto, EVP of Discovery & Safety Assessment at Charles River Laboratories, reported transactions involving the sale of company stock.
NYSE
EVP & Chief People Officer Victoria L. Creamer disposed of 346 shares of Charles River Laboratories common stock to cover tax obligations.
NYSE
Shannon M. Parisotto, CEVP of Charles River Laboratories, reported a transfer of shares to a revocable trust and tax-related dispositions.
NYSE
EVP and Chief Information Officer Mark Mintz disposed of 111 shares of Charles River Laboratories common stock to cover tax obligations.
NYSE
Charles River Laboratories CEO Birgit Girshick reported the disposition of common stock to cover tax obligations related to equity vesting.
NYSE
Michael G. Knell, SVP of Finance and CAO at Charles River Laboratories, reported the disposition of 87 shares to cover tax obligations.
NYSE
Joseph W. LaPlume, EVP of Corporate Strategy & Development at Charles River Laboratories, reported the disposition of 428 shares to cover tax obligations.
NYSE
Nancy C. Andrews, a Director at Charles River Laboratories, reported a transfer of 3,964 common shares to a revocable trust she controls.
NYSE
Charles River Laboratories Director Steven Barg acquired 1,438 shares of common stock at $177.62 per share, increasing his beneficial ownership to 2,865 shares.
NYSE
Charles River Laboratories International, Inc. Director Craig B. Thompson reported a transaction involving company common stock.
NYSE
Director Paul W. Graves acquired 1,438 shares of common stock in Charles River Laboratories International, Inc. on May 8, 2026.
NYSE
Director Abraham Ceesay acquired 1,438 shares of common stock in Charles River Laboratories International, Inc. on May 8, 2026.